Last reviewed · How we verify

NCT04563078

Effect of TMS on PTSD Biomarkers

Completed NA Last updated 9 October 2025
What this trial tests

NA trial testing Transcranial Magnetic Stimulation (TMS) in Post Traumatic Stress Disorder in 63 participants. Completed in 28 September 2025.

Timeline
15 February 2021
Primary endpoint
28 March 2025
28 September 2025

Quick facts

Lead sponsorEmory University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment63
Start date15 February 2021
Primary completion28 March 2025
Estimated completion28 September 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Emory University

Who can join

Adults 18 to 65, any sex, with Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will (1) assess feasibility of a TMS treatment in an underserved population; (2) determine if this TMS treatment protocol improves PTSD symptoms and biological markers of PTSD such as brain functioning and startle responses; (3) define new brain targets for future TMS studies; (4) provide the first data for individual differences, which will help personalize treatment for PTSD patients; (5) improve knowledge of the neurobiology of PTSD and treatment response.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Defining focal brain stimulation targets for PTSD using neuroimaging.
    van Rooij SJH, Sippel LM, McDonald WM, Holtzheimer PE. · · 2021 · cited 20× · PMID 33876868 · DOI 10.1002/da.23159
  2. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults.
    Brown R, Cherian K, Jones K, Wickham R, et al · · 2024 · cited 6× · PMID 39092744 · DOI 10.1002/14651858.cd015040.pub2
  3. Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review.
    Janssen-Aguilar R, Meshkat S, Al-Shamali HF, Perivolaris A, et al · · 2025 · cited 2× · PMID 40879152 · DOI 10.5152/pcp.2025.241027
  4. Towards predicting posttraumatic stress symptom severity using portable EEG-derived biomarkers.
    Peddi A, Sendi MSE, Minton ST, Langhinrichsen-Rohling R, et al · · 2025 · cited 2× · PMID 39948125 · DOI 10.1038/s41598-025-88426-1
  5. Advancing TMS for PTSD - From networks to individuals.
    Sompolpong P, van Rooij SJH. · · 2025 · cited 1× · PMID 41059079 · DOI 10.1016/j.transm.2025.100178
  6. Personalized fMRI-Guided TMS Targeting the Threat Neurocircuitry in PTSD: A Randomized Clinical Trial.
    van Rooij SJH, Langhinrichsen-Rohling R, Minton ST, Hinojosa CA, et al · · 2026 · PMID 41922982 · DOI 10.1176/appi.ajp.20250749

Verify or expand the search:

Other trials of Transcranial Magnetic Stimulation (TMS)

Trials testing the same drug.

Other recruiting trials for Post Traumatic Stress Disorder

Currently open trials in the same condition.

Other Emory University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04563078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing